Suxia Luo

机构：Henan Cancer Hospital · ORCID：0000-0002-3537-2328

发表论文 17 篇 · 总被引 555 次 · h-index 13

代表论文

• [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. (2005 · PubMed · 被引 147)
• miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer (2016 · Oncology Reports · 被引 57)
• LncRNA MCF2L-AS1 aggravates proliferation, invasion and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXM1 signaling axis (2020 · Carcinogenesis · 被引 52)
• A negative feedback loop between miR‐200b and the nuclear factor‐κB pathway via IKBKB / IKK ‐β in breast cancer cells (2015 · FEBS Journal · 被引 48)
• Long noncoding RNA TMPO-AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR-383-5p (2020 · Biomedicine & Pharmacotherapy · 被引 41)
• Clinical significance of the expression of miRNA-21, miRNA-31 and miRNA-let7 in patients with lung cancer (2018 · Saudi Journal of Biological Sciences · 被引 31)